Researchers conducted a small observational study to see how chemotherapy affects the immune system in people with high-grade serous ovarian cancer. They compared immune cells from 33 patients who had surgery before chemotherapy, 57 patients who had chemotherapy before surgery, and 50 healthy people. A smaller group of 17 patients was followed during their chemotherapy cycles.
The study found that chemotherapy was linked to changes in certain immune system markers. Some markers on natural killer (NK) immune cells, which were lower in cancer patients before treatment, returned to levels more like those in healthy people after chemotherapy. The treatment was also linked to increased levels of some proteins that help immune cells kill cancer cells. In a separate finding, higher levels of three specific proteins on tumor cells were linked to longer periods without the cancer getting worse.
It is important to be careful with these results. This was an observational study, which means it can only show links, not prove that chemotherapy caused these changes or that the changes led to better survival. The study was small and did not report on side effects or how well patients tolerated treatment. The findings are early and need to be confirmed in much larger studies. For now, this research offers a clue about how chemotherapy might interact with the immune system in ovarian cancer, which could help guide future studies on combination treatments.